This study provides a new therapeutic option for CML patients resistant to TKIs and highlights the potential of adoptive T cell therapy in CML treatment, as new targets may be uncovered by screening secondary mutations in the BCR-ABL with a broad spectrum of HLA alleles. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.